April 28 (Reuters) - Pfizer said on Tuesday it has settled patent disputes with three generic drugmakers over its blockbuster ...

As Pfizer gears up to defend its patents on transthyretin amyloid cardiomyopathy (ATTR-CM) med tafamidis in court this week, ...

Pfizer inking the last of three settlements to postpone copycats to its transthyretin amyloid cardiomyopathy (ATTR-CM) med ...

Pfizer Inc. (NYSE:PFE) is one of the most active US stocks to buy right now. On April 28, Pfizer entered into settlement ...

Patients taking Pfizer’s Vyndaqel and Vyndamax for a progressive, often fatal form of heart failure will not see cheaper ...

The settlements delay the entry of generic copies of Pfizer’s Vyndamax by almost three years, stabilizing sales of a drug ...

Pfizer’s Vyndamax will be free from generics competition until 2031 in a boost to the company’s revenue streams.

Pfizer has reached settlements with three generic drugmakers, pushing back U.S. market entry of Vyndamax copies until mid-2031, pending other litigation. The move preserves billions in annual revenue ...

Settlements delaying the arrival of generic versions of tafamidis will protect billions in Pfizer revenue and have ...

The pharmaceutical company has been investing in its future growth, but whether its efforts will pay off is a big question ...